Cerlin Roberts Interviews CEO Hans Melo

Cerlin Roberts, CEO of Oxford Global, hosted our CEO, Hans Melo, in her LifeScienceXchange interview series during the NextGen Biomed Conference.

In the interview, Hans Melo explains that artificial intelligence is starting to change drug discovery in important ways, but still faces real challenges like data scarcity and lack of collaboration across the industry. He describes how generative AI can help tackle complex areas like peptide macrocycle design and support every stage of discovery—from finding new targets to creating new types of molecules like peptide therapeutics —while acting as a helpful tool alongside scientists, not replacing them. Looking ahead, he notes that progress will depend on better ways to work with limited data, more data sharing, and stronger collaboration between computational and scientific teams.

About LifeScienceXchange

LifeScienceXchange is a digital platform by Oxford Global that delivers curated industry insights, expert content, and networking opportunities for professionals in biotech and pharmaceutical research and development.

‍

‍